

References

I-220

1. Tepezza™ (teprotumumab-trbw), for injection, for intravenous use [package insert]. Horizon Therapeutics, Inc. Lake Forest, IL. 01/2020.
2. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. teprotumumab-trbw.
3. Micromedex DrugDex Compendium®. 2020. Teprotumumab-trbw.
4. Hayes, Inc. Hayes Emerging Technology Report. Tepezza (Teprotumumab-trbw) for Thyroid Eye Disease. Lansdale, PA: Hayes, Inc.; January, 2020.
5. Smith T, Kahaly G, Ezra D, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. *N Engl J Med*. 2017;376:1748-1761.
6. Douglas R, Kahaly G, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. *N Engl J Med*. 2020;382:341-352.
7. Mitchell A, Goss L, Mathiopoulou L, et al. Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. *J Clin Endocrinol Metab*. 2015;100(3):E458-E462.
8. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
9. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.